Navigation Links
Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs
Date:9/11/2008

INGELHEIM, Germany, September 11 /PRNewswire/ --

- For Non-US Healthcare Media

- Global QUEST Study Reveals Dogs With Congestive Heart Failure Have Significantly Improved Survival Outcomes With Vetmedin(R) (pimobendan)

Veterinarians and dog owners are today welcoming new research that delivers the promise of an extended happy life together for millions of dog owners and their pets. The three-year study demonstrates that dogs suffering from the most common type of heart failure live on average 91% (267 days vs. 140 days) longer when treated with the product Vetmedin(R) (pimobendan) compared with another common treatment option(1).

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/boehringeringelheim/34774/

Results from the QUEST (Quality of Life and Extension of Survival Time) study, published in the current issue of the Journal of Veterinary Internal Medicine, mark a significant milestone in canine cardiac health. Experts report that 25% of all small to medium-sized dogs over the age of seven are likely to suffer from heart disease at some point in their life(2), and 75% of those cases are caused by myxomatous mitral valve disease (MMVD)(3), sometimes known as "valvular insufficiency" or "endocardiosis".

Adrian Boswood from the Royal Veterinary College, London, a Veterinary Cardiology Specialist and a lead-investigator on the study, explains that the independent QUEST trial set out to explore the impact on survival of Vetmedin(R) versus another current treatment, benazepril hydrochloride, an angiotensin-converting enzyme (ACE) inhibitor.

"With QUEST demonstrating that dogs treated with Vetmedin(R) live on average nearly twice as long as those on benazepril(1), it is now time for us as veterinary cardiologists and practising veterinarians to look again at how we are treating our patients suffering from this serious condition."

Dr. Michael O'Grady from the Ontario Veterinary College, University of Guelph, a fellow lead-investigator added, "The QUEST study provides compelling evidence that dogs with the most common form of heart failure should be receiving Vetmedin(R) as an essential part of their treatment regimen."

QUEST is the largest international study ever conducted looking at treatment for congestive heart failure (CHF) caused by MMVD, with 260 dogs studied in 11 countries, across three continents, over a period of three years.

The study was conducted by a team of 32 independent veterinary cardiologists from Australia, Canada, France, Germany and the United Kingdom among other countries.

CHF caused by MMVD most commonly affects older, small breed dogs, including Cavalier King Charles Spaniels, Poodles, Chihuahuas and Dachshunds.(3)

Symptoms of this form of heart failure that dog owners should look for include coughing, reduced tolerance for exercise, anxiety and restlessness during the night, and laboured breathing.(3) If these symptoms are present, it is important that dog owners take their pets to their veterinarians for assessment and treatment.

"Dog owners should be encouraged by the results of the QUEST study, as it demonstrates an important treatment option for lengthening a dog's life when it has this common, debilitating and life-threatening heart condition," said Jens Häggström, Professor of Veterinary Internal Medicine, University of Uppsala and the other lead-investigator on the trial.

Owners now have new information regarding the best chance for enjoying the maximum time possible with their dogs suffering from the most common cause of heart failure.

"With our dogs being so important to our families, we owners should do all we can to make sure our pets are receiving the most effective treatment", said Sally Copland, owner of Fern, an eight-year-old King Charles Spaniel being treated with Vetmedin(R). "None of us want our pets' lives unnecessarily cut short," she added.

The full QUEST study results, providing hard evidence about the importance of using Vetmedin, appear in the September/October 2008 issue of the Journal of Veterinary Internal Medicine.

For more information on the QUEST study and on CHF caused by MMVD, please visit http://www.questtrial.com

Boehringer Ingelheim

Boehringer Ingelheim Animal Health and Boehringer Ingelheim Vetmedica belong to the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of almost 11 billion euro while spending one fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

The animal health business is conducted in more than 20 countries including USA, Canada, France, Germany, UK, Italy, Spain, Mexico, the Nordic countries Japan and China. Since 1955, Boehringer Ingelheim Animal Health is contributing to an adequate supply of safe, nutritious food and is promoting the emotional and physical benefits arising from the human-animal bond.

For more information, please visit http://www.boehringer-ingelheim.com

---------------------------------

References

(1) Häggström J, Boswood A, O'Grady M et al. Effect of Pimobendan or Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart Failure Caused by Naturally Occurring Myxomatous Mitral Valve Disease: The QUEST Study. J Vet Intern Med. 2008;22(5).

(2) Evans T, Johnson C, Wernham J. Cardiovascular Insight: A global study of category prospects. Wood Mackenzie. July 2007.

(3) Häggström J, Kvart C and Pedersen H. "Acquired valvular heart disease" in Ettinger SJ, Feldman EC (Eds). Textbook of veterinary internal medicine: diseases of the dog and cat. 2005 (6th edition).


'/>"/>
SOURCE Boehringer Ingelheim Animal Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senator Bob Dole to Hold Landmark Health Care Forum at Dole Institute of Politics in Kansas
2. Senate Passes Landmark AIDS, TB and Malaria Bill, Says Global AIDS Alliance
3. Kidney Community Thanks Congress for Passing Landmark End Stage Renal Disease (ESRD) Reform
4. Pfizers work on penicillin for World War II becomes a National Historic Chemical Landmark
5. International Training and Development Company, Landmark Education, Mischaracterized as Religion
6. House Passes Landmark Bill on RN Staffing and Patient Safety in Massachusetts Hospitals
7. AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008
8. Boston Scientific Completes Enrollment in Landmark Heart Failure Trial
9. Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide
10. Reps. Smith and Doyle, Autism Society of America Push Landmark Legislation on World Autism Awareness Day
11. Landmark Pediatric Allergies in America Survey Uncovered Negative Impact of Allergy Symptoms on Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its ... Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission ... premise liability and other personal injury cases. These injuries have a major impact ...
(Date:2/22/2017)... ... February 22, 2017 , ... The ... today, as organizations, advocates, and individuals join together to increase recognition about the ... ultimately save lives. , “Today we mark a nationwide movement to raise awareness ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a leader in ... the delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians ... tissue synthesis and provide a faster and more efficient healing process. There are ...
(Date:2/22/2017)... ... February 22, 2017 , ... The SeniorCare Investor will ... Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording of the ... of the Interactive Webinar Series. , If you want to find out what really ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is ... combat-related PTSD. , Established in 1977, our organization was at the forefront in ... returning to civilian life were evident and served as the catalyst for the ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Patient Monitoring Equipment ... monitor physiological signs. These devices are either used as ... monitoring is one of the key factors for the ... market. Hence, vendors are developing technologically advanced products that ... send test results on time and provide better patient ...
(Date:2/21/2017)... Feb. 21, 2017 Micro Guide Catheters ... http://www.reportlinker.com/p04711314-summary/view-report.html Micro Guide Catheters ... hospitals, specialty clinics and ambulatory surgery centers etc. ... tip. The selection of micro guide catheter depends ... in human body. Micro guide catheters are available ...
(Date:2/21/2017)... IBM ) Research has today announced new research developments ... retina. The Melbourne based IBM researchers ... in retina images, which could in the future offer doctors ... who may be at risk of eye diseases – such ... world. The research began in 2015 and ...
Breaking Medicine Technology: